Polynucleotides encoding recombinant respiratory syncytial viruses expressing immune modulatory molecules

US7465794B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Peter L. Collins · Kensington, US
• Alexander Bukreyev · Rockville, US
• Brian R. Murphy · Bethesda, US
• Stephen S. Whitehead · Montgomery Village, US

Key dates

• Filing date: Jan 8, 2004
• Grant date: Dec 16, 2008
• Expiry date: Jan 8, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.